Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times

Molecular Cancer

Volumn 8, Issue , 2009, Pages 72-

  Selvarajah, Gayathri T ^a,b   Kirpensteijn, Jolle ^a   van Wolferen, Monique E ^a   Rao, Nagesha A S ^a   Fieten, Hille ^a   Mol, Jan A ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COMPLEMENTARY DNA; CYTOKINE; INTEGRIN; WNT PROTEIN;

ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DEREGULATION; DISEASE COURSE; DNA MICROARRAY; DOG; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; MALE; METASTASIS; MOLECULAR MECHANICS; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PROGNOSIS; SIGNAL TRANSDUCTION; SPECIES COMPARISON; SURVIVAL TIME; TUMOR CLASSIFICATION; UPREGULATION;

ANIMALS; BONE NEOPLASMS; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; DOGS; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MODELS, GENETIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

CANIS FAMILIARIS;

EID: 70350116110     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-72     Document Type: Article

References (69)

1. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ, Zody MC, Mauceli E, Xie X, Breen M, Wayne RK, Ostrander EA, Ponting CP, Galibert F, Smith DR, DeJong PJ, Kirkness E, Alvarez P, Biagi T, Brockman W, Butler J, Chin CW, Cook A, Cuff J, Daly MJ, DeCaprio D, Gnerre S. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005, 438:803-819. 10.1038/nature04338, 16341006.
2. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, Niemi S, Comstock KE, Ostrander E, Westmoreland S, Withrow S. The dog as a cancer model. Nat Biotechnol 2006, 24:1065-1066. 10.1038/nbt0906-1065b, 16964204.
3. Brodey RS, Riser WH. Canine osteosarcoma. A clinicopathologic study of 194 cases. Clin Orthop Relat Res 1969, 62:54-64. 10.1097/00003086-196901000-00008, 5251443.
4. Tjalma RA. Canine bone sarcoma: estimation of relative risk as a function of body size. J Natl Cancer Inst 1966, 36:1137-1150.
5. Dickerson ME, Page RL, LaDue TA, Hauck ML, Thrall DE, Stebbins ME, Price GS. Retrospective analysis of axial skeleton osteosarcoma in 22 large-breed dogs. J Vet Intern Med 2001, 15:120-124. 10.1892/0891-6640(2001)015<0120:RAOASO>2.3.CO;2, 11300594.
6. Dorfman SK, Hurvitz AI, Patnaik AK. Primary and secondary bone tumours in the dog. J Small Anim Pract 1977, 18:313-326. 10.1111/j.1748-5827.1977.tb05890.x, 267798.
7. Brodey RS. The use of naturally occurring cancer in domestic animals for research into human cancer: general considerations and a review of canine skeletal osteosarcoma. Yale J Biol Med 1979, 52:345-361. 2595482, 115162.
8. Pirkey-Ehrhart N, Withrow SJ, Straw RC, Ehrhart EJ, Page RL, Hottinger HL, Hahn KA, Morrison WB, Albrecht MR, Hedlund CS, Hammer AS, Holmberg DL, Moore AS, King RR, Klausner JS. Primary rib tumors in 54 dogs. J Am Anim Hosp Assoc 1995, 31:65-69.
9. Madewell BR, Leighton RL, Theilen GH. Amputation and doxorubicin for treatment of canine and feline osteogenic sarcoma. Eur J Cancer 1978, 14:287-293.
10. La Rue SM, Withrow SJ. Tumors of the skeletal system. Clinical Veterinary Oncology 1989, 234-252. Philadelphia: JB Lippincott, Withrow SJ, MacEwen G.
11. Ling GV, Morgan JP, Pool RR. Primary bone rumors in the dog: a combined clinical, radiographic, and histologic approach to early diagnosis. J Am Vet Med Assoc 1974, 165:55-67.
12. Brodey RS, Abt DA. Results of surgical treatment in 65 dogs with osteosarcoma. J Am Vet Med Assoc 1976, 168:1032-1035.
13. Kirpensteijn J, Teske E, Kik M, Klenner T, Rutteman GR. Lobaplatin as an adjuvant chemotherapy to surgery in canine appendicular osteosarcoma: a phase II evaluation. Anticancer Res 2002, 22:2765-2770.
14. Bacon NJ, Ehrhart NP, Dernell WS, Lafferty M, Withrow SJ. Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999-2006). J Am Vet Med Assoc 2008, 232:1504-1510. 10.2460/javma.232.10.1504, 18479240.
15. Shapiro W, Fossum TW, Kitchell BE, Couto CG, Theilen GH. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988, 192:507-511.
16. Spodnick GJ, Berg J, Rand WM, Schelling SH, Couto G, Harvey HJ, Henderson RA, MacEwen G, Mauldin N, McCaw DL, Moore AS, Morrison WB, Norris AM, O'Bradovich J, O'Keefe DA, Page RL, Ruslander D, Klausner JS, Straw RC, Thompson JP, Withrow SJ. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 1992, 200:995-999.
17. Kraegel SA, Madewell BR, Simonson E, Gregory CR. Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). J Am Vet Med Assoc 1991, 199:1057-1059.
18. Kirpensteijn J, Timmermans-Sprang EP, van Garderen E, Rutteman GR, Lantinga-van Leeuwen IS, Mol JA. Growth hormone gene expression in canine normal growth plates and spontaneous osteosarcoma. Mol Cell Endocrinol 2002, 197:179-185. 10.1016/S0303-7207(02)00269-1, 12431811.
19. Yang R, Hoang BH, Kubo T, Kawano H, Chou A, Sowers R, Huvos AG, Meyers PA, Healey JH, Gorlick R. Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 2007, 121:943-954. 10.1002/ijc.22749, 17410535.
20. Wolf M, El-Rifai W, Tarkkanen M, Kononen J, Serra M, Eriksen EF, Elomaa I, Kallioniemi A, Kallioniemi OP, Knuutila S. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet Cytogenet 2000, 123:128-132. 10.1016/S0165-4608(00)00319-8, 11156738.
21. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 2001, 61:3750-3759.
22. Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Wong KK, Lau CC. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 2005, 65:8142-8150. 10.1158/0008-5472.CAN-05-0985, 16166288.
23. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, Ramsey KE, Antonescu CR, Chen W, Healey JH, Daluski A, Berens ME, Macdonald TJ, Gorlick R, Stephan DA. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 2005, 65:1748-1754. 10.1158/0008-5472.CAN-04-2463, 15753370.
24. Rajkumar T, Yamuna M. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. Anticancer Drugs 2008, 19:257-265. 10.1097/CAD.0b013e3282f435b6, 18510171.
25. Srivastava A, Fuchs B, Zhang K, Ruan M, Halder C, Mahlum E, Weber K, Bolander ME, Sarkar G. High WT1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis. Clin Cancer Res 2006, 12:4237-4243. 10.1158/1078-0432.CCR-05-2307, 16857797.
26. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20:776-790. 10.1200/JCO.20.3.776, 11821461.
27. Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop Relat Res 1991, 159-168.
28. MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990, 9:125-136. 10.1007/BF00046339, 2253312.
29. Loukopoulos P, Robinson WF. Clinicopathological relevance of tumour grading in canine osteosarcoma. J Comp Pathol 2007, 136:65-73. 10.1016/j.jcpa.2006.11.005, 17270206.
30. Garge NR, Page GP, Sprague AP, Gorman BS, Allison DB. Reproducible clusters from microarray research: whither?. BMC Bioinformatics 2005, 6(Suppl 2):S10. 10.1186/1471-2105-6-S2-S10, 1637038, 16026595.
31. Sennoune SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya MN, Martinez-Zaguilan R. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 2004, 286:C1443-1452. 10.1152/ajpcell.00407.2003, 14761893.
32. Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer 2007, 7:429-440. 10.1038/nrc2148, 17522712.
33. Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 2005, 205:74-81. 10.1002/path.1672, 15532096.
34. Walters DK, Steinmann P, Langsam B, Schmutz S, Born W, Fuchs B. Identification of potential chemoresistance genes in osteosarcoma. Anticancer Res 2008, 28:673-679.
35. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006, 6:1075-1085. 10.1586/14737140.6.7.1075, 16831079.
36. Meyer B, Murua Escobar H, Hauke S, Richter A, Winkler S, Rogalla P, Flohr AM, Bullerdiek J, Nolte I. Expression pattern of the HMGB1 gene in sarcomas of the dog. Anticancer Res 2004, 24:707-710.
37. Imamura T, Izumi H, Nagatani G, Ise T, Nomoto M, Iwamoto Y, Kohno K. Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. J Biol Chem 2001, 276:7534-7540. 10.1074/jbc.M008143200, 11106654.
38. Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M, Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev 1998, 12:462-472. 10.1101/gad.12.4.462, 316524, 9472015.
39. Krynetskaia N, Xie H, Vucetic S, Obradovic Z, Krynetskiy E. High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs. Mol Pharmacol 2008, 73:260-269. 10.1124/mol.107.041764, 2210013, 17951356.
40. Johansson K, Ahlen K, Rinaldi R, Sahlander K, Siritantikorn A, Morgenstern R. Microsomal glutathione transferase 1 in anticancer drug resistance. Carcinogenesis 2007, 28:465-470. 10.1093/carcin/bgl148, 16920737.
41. Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 1997, 79:2336-2344. 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J, 9191521.
42. Shoieb AM, Hahn KA, Van Laack RL, Barnhill MA. In vitro reversal of glutathione-S-transferase-mediated resistance in canine osteosarcoma (COS31) cells. In Vivo 1998, 12:455-462.
43. Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J Biol Chem 2005, 280:39373-39379. 10.1074/jbc.M500022200, 16176931.
44. Kaul Z, Yaguchi T, Kaul SC, Wadhwa R. Quantum dot-based protein imaging and functional significance of two mitochondrial chaperones in cellular senescence and carcinogenesis. Ann N Y Acad Sci 2006, 1067:469-473. 10.1196/annals.1354.067, 16804028.
45. Uozaki H, Ishida T, Kakiuchi C, Horiuchi H, Gotoh T, Iijima T, Imamura T, Machinami R. Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract 2000, 196:665-673.
46. Trieb K, Gerth R, Windhager R, Grohs JG, Holzer G, Berger P, Kotz R. Serum antibodies against the heat shock protein 60 are elevated in patients with osteosarcoma. Immunobiology 2000, 201:368-376.
47. McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J, London CA. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer 2009,
48. Yan T, Wunder JS, Gokgoz N, Gill M, Eskandarian S, Parkes RK, Bull SB, Bell RS, Andrulis IL. COPS3 amplification and clinical outcome in osteosarcoma. Cancer 2007, 109:1870-1876. 10.1002/cncr.22595, 17366602.
49. Zhang J, Chen X, Kent MS, Rodriguez CO, Chen X. Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor. Mol Cancer Res 2009, 7:67-78. 10.1158/1541-7786.MCR-08-0347, 19147538.
50. Mendoza S, Konishi T, Dernell WS, Withrow SJ, Miller CW. Status of the p53, Rb and MDM2 genes in canine osteosarcoma. Anticancer Res 1998, 18:4449-4453.
51. Kirpensteijn J, Kik M, Teske E, Rutteman GR. TP53 gene mutations in canine osteosarcoma. Vet Surg 2008, 37:454-460. 10.1111/j.1532-950X.2008.00407.x, 18986312.
52. Chen K, Fallen S, Abaan HO, Hayran M, Gonzalez C, Wodajo F, MacDonald T, Toretsky JA, Uren A. Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer 2008, 51:349-355. 10.1002/pbc.21595, 18465804.
53. Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza B, Meyers PA, Gorlick R. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004, 64:2734-2739. 10.1158/0008-5472.CAN-03-1952, 15087387.
54. Hoang BH, Kubo T, Healey JH, Sowers R, Mazza B, Yang R, Huvos AG, Meyers PA, Gorlick R. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004, 109:106-111. 10.1002/ijc.11677, 14735475.
55. Fan TM, Barger AM, Fredrickson RL, Fitzsimmons D, Garrett LD. Investigating CXCR4 expression in canine appendicular osteosarcoma. J Vet Intern Med 2008, 22:602-608. 10.1111/j.1939-1676.2008.0089.x, 18466248.
56. Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mitola S, Grignani G, Surrenti N, Sangiolo D, Bussolino F, Piacibello W, Aglietta M. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res 2005, 11:490-497.
57. Maraqa L, Donnellan CF, Peter MB, Speirs V. Clinicians' guide to microarrays. Surg Oncol 2006, 15:205-210. 10.1016/j.suronc.2006.12.003, 17291747.
58. van't Veer LJ, Dai H, Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
59. Kirpensteijn J, Kik M, Rutteman GR, Teske E. Prognostic significance of a new histologic grading system for canine osteosarcoma. Vet Pathol 2002, 39:240-246. 10.1354/vp.39-2-240, 12009062.
60. Rao NA, van Wolferen ME, Ham R, van Leenen D, Groot Koerkamp MJ, Holstege FC, Mol JA. cDNA microarray profiles of canine mammary tumour cell lines reveal deregulated pathways pertaining to their phenotype. Anim Genet 2008, 39:333-345. 10.1111/j.1365-2052.2008.01733.x, 18462483.
61. Fang H, Fan X, Guo L, Shi L, Perkins R, Ge W, Dragan YP, Tong W. Self-self hybridization as an alternative experiment design to dye swap for two-color microarrays. Omics 2007, 11:14-24. 10.1089/omi.2006.0002, 17411393.
62. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121. 10.1073/pnas.091062498, 33173, 11309499.
63. Morey JS, Ryan JC, Van Dolah FM. Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR. Biol Proced Online 2006, 8:175-193. 10.1251/bpo126, 1779618, 17242735.
64. Slonim DK. From patterns to pathways: gene expression data analysis comes of age. Nat Genet 2002, 32(Suppl):502-508. 10.1038/ng1033, 12454645.
65. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000, 132:365-386.
66. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002, 30:e36. 10.1093/nar/30.9.e36, 113859, 11972351.
67. Ptitsyn AA, Weil MM, Thamm DH. Systems biology approach to identification of biomarkers for metastatic progression in cancer. BMC Bioinformatics 2008, 9(Suppl 9):S8. 10.1186/1471-2105-9-S9-S8, 2537559, 18793472.
68. Schaefer KL, Eisenacher M, Braun Y, Brachwitz K, Wai DH, Dirksen U, Lanvers-Kaminsky C, Juergens H, Herrero D, Stegmaier S, Koscielniak E, Eggert A, Nathrath M, Gosheger G, Schneider DT, Bury C, Diallo-Danebrock R, Ottaviano L, Gabbert HE, Poremba C. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008, 44:699-709.
69. Leek JT, Monsen E, Dabney AR, Storey JD. EDGE: extraction and analysis of differential gene expression. Bioinformatics 2006, 22:507-508. 10.1093/bioinformatics/btk005, 16357033.